Top

Published in:

01-12-2021 | Adenovirus | Original Article

Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model

Authors: Hai-Jun Hu, Xiu Liang, Hai-Lang Li, Huai-Yuan Wang, Jin-Fa Gu, Lan-Ying Sun, Jing Xiao, Jin-Qing Hu, Ai-Min Ni, Xin-Yuan Liu

Published in: Cancer Immunology, Immunotherapy | Issue 12/2021

Abstract

Although the recent treatment in melanoma through the use of anti-PD-1 immunotherapy is successful, the efficacy of this approach remains to be improved. Here, we explore the feasibility of combination strategy with the armed oncolytic adenovirus ZD55-IL-24 and PD-1 blockade. We find that combination therapy with localized ZD55-IL-24 and systemic PD-1 blockade leads to synergistic inhibition of both local and distant established tumors in B16-bearing immunocompetent mouse model. Our further mechanism investigation reveals that synergistic therapeutic effect is associated with marked promotion of tumor immune infiltration and recognition in both local and distant tumors as well as spleens. PD-1 blockade has no obvious effect on promotion of tumor immune infiltration and recognition. Localized therapy with ZD55-IL-24, however, can help PD-1 blockade to overcome the limitation of relatively low tumor immune infiltration and recognition. This study provides a rationale for investigation of such combination therapy in the clinic.

Available only for authorised users

Zhu L, Kalimuthu S, Gangadaran P, Oh JM, Lee HW, Baek SH, Jeong SY, Lee SW, Lee J, Ahn BC (2017) Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7(10):2732–2745. https://doi.org/10.7150/thno.18752CrossRefPubMedPubMedCentral

Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5–24. https://doi.org/10.1634/theoncologist.2010-0190CrossRefPubMedPubMedCentral

Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463–482. https://doi.org/10.1038/nrclinonc.2017.43CrossRefPubMed

Sullivan RJ, Flaherty KT (2015) Immunotherapy: anti-PD-1 therapies-a new first-line option in advanced melanoma. Nat Rev Clin Oncol 12(11):625–626. https://doi.org/10.1038/nrclinonc.2015.170CrossRefPubMed

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ (2016) Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22(12):1402–1410. https://doi.org/10.1038/nm.4200CrossRefPubMedPubMedCentral

Gao L, Zhang C, Gao D, Liu H, Yu X, Lai J, Wang F, Lin J, Liu Z (2016) Enhanced anti-tumor efficacy through a combination of integrin αvβ6-targeted photodynamic therapy and immune checkpoint inhibition. Theranostics 6(5):627–637. https://doi.org/10.7150/thno.14792CrossRefPubMedPubMedCentral

Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M (2017) Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 23(1):124–136. https://doi.org/10.1158/1078-0432.CCR-15-1535CrossRefPubMed

Guo Z, Wang H, Meng F, Li J, Zhang S (2015) Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med 13:247. https://doi.org/10.1186/s12967-015-0613-yCrossRefPubMedPubMedCentral

Buchbinder EI, Hodi FS (2016) Melanoma in 2015: Immune-checkpoint blockade-durable cancer control. Nat Rev Clin Oncol 13(2):77–78. https://doi.org/10.1038/nrclinonc.2015.237CrossRefPubMed

10.

Ribas A, Robert C, Hodi FS, Wolchok JD, Hwu WJ (2015) Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 33(2):141–147. https://doi.org/10.1002/pi.1995.210370209CrossRef

11.

Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH (2016) Talimogene Laherparepvec in combination with Ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34(22):2619–2626. https://doi.org/10.1200/JCO.2016.67.1529CrossRefPubMedPubMedCentral

12.

Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658–670. https://doi.org/10.1038/nbt.2287CrossRefPubMedPubMedCentral

13.

Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY (2003) An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13(6):481–489. https://doi.org/10.1038/sj.cr.7290191CrossRefPubMed

14.

Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642–662. https://doi.org/10.1038/nrd4663CrossRefPubMedPubMedCentral

15.

Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D (2003) E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21(11):1328–1335. https://doi.org/10.1038/nbt887CrossRefPubMed

16.

Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, Qian Q, Qian C, Liu X (2005) Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16(7):845–858. https://doi.org/10.1089/hum.2005.16.845CrossRefPubMed

17.

Liu XY, Pestka S, Shi YF (2013) Recent advances in cancer research and therapy. Tsinghua University Press, Beijing

18.

Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X (2008) Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 22(2):361–369. https://doi.org/10.1038/sj.leu.2405034CrossRefPubMed

19.

Yuan S, Fang X, Xu Y, Ni A, Liu XY, Chu L (2016) An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells. Oncotarget 7(37):60491–60502. https://doi.org/10.18632/oncotarget.11134CrossRefPubMedPubMedCentral

20.

Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY (2010) An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol 49(1):91–99. https://doi.org/10.3109/02841860903246557CrossRefPubMed

21.

Young L, Sung J, Stacey G, Masters JR (2010) Detection of mycoplasma in cell cultures. Nat Protoc 5(5):929–934. https://doi.org/10.1038/nprot.2010.43CrossRefPubMed

22.

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412. https://doi.org/10.1371/journal.pbio.1000412CrossRefPubMedPubMedCentral

23.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226–232. https://doi.org/10.1126/scitranslmed.3008095CrossRef

24.

Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W (2018) CD4⁺ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18(10):635–647. https://doi.org/10.1038/s41577-018-0044-0CrossRefPubMed

25.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416. https://doi.org/10.1038/nrclinonc.2016.217CrossRefPubMedPubMedCentral

26.

Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252. https://doi.org/10.1038/nri3174CrossRefPubMedPubMedCentral

27.

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7–24. https://doi.org/10.1038/s41577-019-0210-zCrossRefPubMed

28.

Ohue Y, Nishikawa H (2019) Regulatory T (T_reg) cells in cancer: can T_reg cells be a new therapeutic target? Cancer Sci 110(7):2080–2089. https://doi.org/10.1111/cas.14069CrossRefPubMedPubMedCentral

29.

Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109–118. https://doi.org/10.1038/cr.2016.151CrossRefPubMed

30.

Kumar P, Bhattacharya P, Prabhakar BS (2018) A comprehensive review on the role of co-signaling receptors and T_reg homeostasis in autoimmunity and tumor immunity. J Autoimmun 95:77–99. https://doi.org/10.1016/j.jaut.2018.08.007CrossRefPubMedPubMedCentral

31.

Murphy K (2012) Janeway’s immunobiology, 8th edn. Garland Science, London

32.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC (2018) Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med 10(422):eaao1641. https://doi.org/10.1126/scitranslmed.aao1641CrossRefPubMed

33.

Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol 19(4):493–502. https://doi.org/10.1093/neuonc/now179CrossRefPubMed

34.

Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL (2017) Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 8:14754. https://doi.org/10.1038/ncomms14754CrossRefPubMedPubMedCentral

35.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med 10(422):eaam7577. https://doi.org/10.1126/scitranslmed.aam7577CrossRefPubMedPubMedCentral

36.

Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18(4):518–527. https://doi.org/10.1093/neuonc/nov173CrossRefPubMed

37.

Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486. https://doi.org/10.1038/nrclinonc.2016.58CrossRefPubMed

38.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R (2016) Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 24(1):166–174. https://doi.org/10.1038/mt.2015.156CrossRefPubMed

39.

Quetglas JI, Labiano S, Aznar M, Bolaños E, Azpilikueta A, Rodriguez I, Casales E, Sánchez-Paulete AR, Segura V, Smerdou C, Melero I (2015) Virotherapy with a semliki forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade. Cancer Immunol Res 3(5):449–454. https://doi.org/10.1158/2326-6066.Cir-14-0216CrossRefPubMed

40.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A (2018) TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 7(5):e1412902. https://doi.org/10.1080/2162402x.2017.1412902CrossRefPubMedPubMedCentral

41.

Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R (2017) Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther 24(1):21–30. https://doi.org/10.1038/gt.2016.70CrossRefPubMed

42.

Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V (2020) Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy. Cancer Res 80(12):2575–2585. https://doi.org/10.1158/0008-5472.Can-19-2062CrossRefPubMed

43.

Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC (2019) Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 18(9):689–706. https://doi.org/10.1038/s41573-019-0029-0CrossRefPubMed

44.

Hu HJ, Liang X, Li HL, Du CM, Hao JL, Wang HY, Gu JF, Ni AM, Sun LY, Xiao J, Hu JQ, Yuan H, Dai YS, Jin XT, Zhang KJ, Liu XY (2020) The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing. Cell Death Dis 11(11):1022. https://doi.org/10.1038/s41419-020-03223-0CrossRefPubMedPubMedCentral

45.

Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, Sarkar D, Grant S, Dent P, Curiel DT, Fisher PB (2010) Mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 21(5):381–391. https://doi.org/10.1016/j.cytogfr.2010.08.004CrossRefPubMedPubMedCentral

Title: Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Authors: Hai-Jun Hu
Xiu Liang
Hai-Lang Li
Huai-Yuan Wang
Jin-Fa Gu
Lan-Ying Sun
Jing Xiao
Jin-Qing Hu
Ai-Min Ni
Xin-Yuan Liu
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Adenovirus
Melanoma
Melanoma
Published in: Cancer Immunology, Immunotherapy / Issue 12/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-02946-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2021

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer

Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma

Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas

Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer